Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase ALK Fusion Protein
A Multi-Center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 And Anti-CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
An Open-Label, Phase I, Multi-Center Study to Determine in Relapsed/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome or B-Cell Non-Hodgkin Lymphoma Patients the Recommended Dose of CYAD-02 After A Non-Myeloablative Preconditioning Chemotherapy Followed By A Potential CYAD-02 Consolidation Cycle for Non-Progressive Patients CYCLE-1 ? CYAD-02 NKG2D CAR-T Clinical dEvelopment
A Phase I Study Evaluating SC262, a Hypoimmune, Allogeneic CD22-directed CAR T Cell Therapy, in Relapsed and/or Refractory Non-Hodgkin?s Lymphoma VIVID
Study Type: Treatment
Phase: I
NCTID: NCT06285422
Principal Investigator:
Forat Lutfi
A Phase II Single Arm Proof Of Concept, Safety, Efficacy, Multicenter Study Of Brentuximab Vedotin As Consolidation Therapy After Autologous Stem Cell Transplant In CD 30 Expressing Peripheral T Cell Lymphomas BRENTICON-T
Study Type: Treatment
Phase: II
NCTID: NCT04334174
Principal Investigator:
Marc Hoffmann
A Randomized Phase II Study of CDX-1127 Varlilumab in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-cell Lymphomas
An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-Directed Autologous Chimeric Antigen Receptor CAR T-Cell Therapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma FIRCE-1
A Phase I Dose Escalation and Expanded Cohort Study of Pf-06821497 in the Treatment of Adult Patients with Relapsed/Refractory Small Cell Lung Cancer SCLC, Castration Resistant Prostate Cancer CRPC and Follicular Lymphoma FL
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 Directed CAR T-Cell Therapy
Study Type: Other
Phase: N/A
NCTID: NCT02445222
Principal Investigator:
Gary Myers